Nasonex is a drug with anti-inflammatory and anti-allergic effect, used in the treatment of ENT diseases.
Release form and composition
Nasonex is produced in the form of a nasal dosage spray (0.050 mg / 1 dose): a suspension of white or white almost colored (in plastic bottles of 10 g (60 doses), 1 bottle in a cardboard pack, or 18 g (120 doses), 1-3 bottles in a carton box).
The composition of 1000 mg spray includes:
- Active substance: mometasone furoate (in the form of monohydrate, micronized) - 0.5 mg;
- Auxiliary components: dispersed cellulose (microcrystalline cellulose treated with carmellose sodium) - 20 mg; glycerol - 21 mg; citric acid monohydrate - 2 mg; sodium citrate dihydrate - 2.8 mg; polysorbate 80 - 0.1 mg; benzalkonium chloride (as a 50% solution) - 0.2 mg; purified water - 950 mg.
Indications for use
- Allergic rhinitis (seasonal and year-round) in adults and children from 2 years of age (treatment);
- Acute sinusitis or exacerbation of chronic in adults (including elderly patients) and children from 12 years old (as an auxiliary therapeutic agent for treatment with antibiotic drugs);
- Seasonal allergic rhinitis (moderate and severe) in adults and children from 12 years old (prevention, it is recommended to carry out 14-28 days before the expected start of the dusting season);
- Acute rhinosinusitis with mild and mild symptoms in the absence of signs of severe bacterial infection in adults and children from 12 years of age;
- Polyposis of the nose, accompanied by impaired sense of smell and nasal breathing in adults.
- Nasal trauma with damage to the nasal mucosa or recent surgery (the drug can be used after wound healing, which is due to the effect of Nasonex on tissue regeneration processes);
- Age up to 2 years (seasonal and year-round allergic rhinitis), up to 12 years (acute sinusitis or exacerbation of chronic sinusitis) or up to 18 years (polyposis), due to the lack of data on the safety and efficacy of Nasonex in this age group of patients;
- Hypersensitivity to the drug.
Nasonex can be prescribed to nursing and pregnant women only after assessing the benefit / risk ratio for mother and child.
Spray should be used with caution in the presence of the following diseases / conditions:
- Tuberculosis infection (active or latent) of the respiratory tract;
- Untreated fungal, bacterial, systemic viral infection or infections caused by herpes simplex (Herpes simplex) with eye damage (with the listed infections as an exception, Nasonex can be prescribed by a doctor);
- Untreated local infections involving the nasal mucosa.
Dosing and Administration
Nasonex is administered intranasally. Dosing regimen is determined by indications. When using the drug in young children may require adult care.
When treating seasonal or year-round allergic rhinitis, the recommended therapeutic and prophylactic dose for adults and children from 12 years of age is 2 inhalations (0.050 mg each) in each nostril, the frequency of use is 1 time per day (total daily dose is 0.2 mg). In cases of insufficient therapeutic effect, a single dose is increased to 4 inhalations in each nostril. After improvement, for the maintenance treatment, it is possible to reduce the average therapeutic dose by 2 times. Children 2-11 years old are usually prescribed 1 inhalation per each nostril once a day. As a rule, the onset of action of Nasonex is noted clinically within 12 hours after the first use of the drug.
When conducting adjuvant therapy of acute sinusitis or exacerbation of chronic sinusitis, adults (including elderly patients) and children from 12 years old are prescribed 2 times a day, 2 inhalations in each nostril (total dose - 0.4 mg per day). If it is not possible to reduce the severity of symptoms, a single dose may be increased by 2 times. After improvement, its decrease is shown.
In the treatment of acute rhinosinusitis, which is not accompanied by signs of severe bacterial infection, adults are prescribed 2 times a day, 2 inhalations (total dose - 0.4 mg per day). In case of deterioration it is recommended to consult a doctor.
For the treatment of nasal polyposis, adults (including elderly patients) are prescribed 2 times a day, 2 inhalations (total dose - 0.4 mg per day). After improving the condition, the multiplicity of application of Nasonex is reduced by 2 times.
Before the first use of the drug, it is necessary to calibrate, for which you need to press the dosing device up to 10 times. The appearance of spray indicates readiness for use. For interruptions in use for more than 14 days, press the dispensing nozzle several times until a spray appears.
For the procedure you need to tilt your head and inject the drug as recommended by your doctor.
Before each procedure, the vial should be shaken vigorously.
In order to avoid the malfunction of the dosing nozzle, it is important to clean it regularly, for which you first remove the cap protecting the nozzle, then the spray tip. The tip is thoroughly washed in warm water and rinsed under running water.
Do not open the nasal applicator with a needle or other sharp object, as this will cause damage to the applicator and incorrect dosing of the drug.
Depending on age, the following disorders may develop during therapy:
- Adults and adolescents: pharyngitis, headache, burning sensation in the nose, nosebleeds (obvious bleeding, and discharge of blood clots or blood-stained mucus), irritation of the nasal mucosa, ulceration of the nasal mucosa. As a rule, nosebleeds stop on their own and are not severe;
- Children: sneezing, nosebleeds, feeling of irritation in the nose, headache.
Regardless of age, nasonex can also develop:
- Seldom: immediate-type hypersensitivity reactions (in particular, dyspnea, bronchospasm);
- Very seldom: disturbances of smell and taste, angioedema, anaphylaxis; perforation of the nasal septum or increased intraocular pressure.
With prolonged use of Nasonex, it is necessary to periodically examine the nasal mucosa at the ENT doctor. In the event of a local fungal infection of the pharynx or nose, it is recommended to interrupt treatment and initiate special therapy. Long-lasting irritation of the mucous membrane of the pharyngeal cavity and nose is the basis for the cancellation of treatment.
With prolonged drug therapy, signs of suppression of the hypothalamic-pituitary-adrenal system are not observed.
Patients who switch to the use of Nasonex after prolonged therapy with systemic glucocorticosteroids require special attention. In such patients, the abolition of glucocorticosteroids of systemic action can lead to a lack of adrenal function, which can take several months to recover in the future. If there are signs of adrenal insufficiency, you need to resume taking systemic corticosteroids and take other measures.
In addition, in the implementation of such a transition, some patients may develop symptoms of withdrawal of systemic corticosteroids (in particular, in the form of muscle and / or joint pain, feelings of fatigue, depression), despite the reduction in the severity of symptoms associated with lesions of the nasal mucosa. In such cases, treatment with Nasonex should be continued. Sometimes a change of therapy can reveal previously developed allergic diseases, such as eczema and allergic conjunctivitis, which were previously masked by systemic-glucocorticosteroid therapy.
During the use of the drug there is an increased risk of infection when in contact with patients with infectious diseases, including chicken pox and measles. If such contact has occurred, you must notify the doctor.
If signs of severe bacterial infection develop (for example, in the form of sharp and persistent pain on one side of the face, fever, toothache, swelling in the periorbital or orbital region), it is necessary to consult a doctor immediately.
Simultaneous use of Nasonex with loratadine patients is usually well tolerated. However, no effect of the drug on the concentration of loratadine was noted.
Terms and conditions of storage
Keep out of reach of children at 2-25 ° C.
Shelf life - 2 years.